Halaven

Eribulin (Halaven)

Eribulin is a chemotherapy drug. It's also known as Halaven. It's a treatment for breast cancer and liposarcoma that has: spread to surrounding tissue (locally advanced cancer) spread to other areas ... read more

Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022

The estimated 5-year relative survival rate for women with mBC is 28%. About HALAVEN® (eribulin mesylate) Injection SHARE THIS POST Find News News ... read more

Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022

evaluating the efficacy of eribulin mesylate (marketed as HALAVEN ®) versus other chemotherapies (Treatment of Physician's Choice [TPC], capecitabine, and vinorelbine, respectively) in patients ... read more

Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022

The estimated 5-year relative survival rate for women with mBC is 28%. HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic breast cancer (mBC ... read more

Who Owns the Ocean’s Genes? Tension on the High Seas

Countries are struggling with how to share genetic code from myriad ocean creatures, which could lead to billion-dollar drugs ... read more

Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022

Viele Anleger setzen deshalb auf den Aktiv verwalteten Global Inflation Protection Basket. Informieren Sie sich über die breit gestreute Auswahl an robusten Aktien & ETFs. read more